NCI issues grant for radio-immuno-guided surgery agent development

Editorial Staff | | Health Imaging | Molecular Imaging

Navidea Biopharmaceuticals, a biopharmaceutical company focused on diagnostic radiopharmaceuticals, has received a Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI), National Institutes of Health, to fund the development of its radio-immuno-guided surgery (RIGS) monoclonal antibody targeting agent for use in detecting metastatic sites in colorectal cancer.

The SBIR grant has the potential for grant money up to a total of $1.5 million over three years if fully funded, according to Navidea. The first-year Phase I funding of $315,000, which has already been approved, is expected to enable the Dublin, Ohio-based company to complete preclinical bridging activities using a RIGS tumor-antigen-targeted monoclonal antibody and prepare a standardization clinical trial protocol. Second and third year (Phase II) funding of up to $1.2 million is contingent upon meeting certain Phase I success criteria, including Institutional Review Board approval of the clinical trial protocol.

Editorial Staff

Related Content

Experts update AUC for amyloid, tau PET imaging for first time in more than a decade
Repurposed radiotracer lights up treatment-resistant tumors 'like a Christmas tree'
Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.